Dry Eye

Exploring strategies for effective management of a multifaceted condition.

The study also discovered a need for more blatant labeling on e-liquid containers to help reduce accidental contact with the ocular surface.

The company plans to finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

The solution, CAM360 AmnioGraft, is hydrated and shelf-stable without need for refrigeration.

The trial, in part of the ASTRO study, will evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment 0.5%.

One of the resources provided by the partnership is a Dry Eye Wheel, which provides mitigation, measurement, and management processes to inform the treatment of dry eye disease.

The study demonstrated sustained safety and efficacy of cyclosporine ophthalmic solution (Vevye) 0.1%, with many patients now entering their sixth refill cycle, according to the company.

The novel therapy for dry eye is a cross-linked hyaluronic acid derivative cleared by the FDA.

The launch of the nutritional supplement follows a clinical trial that demonstrated healthy tear production and provided noticeable relief of dry eye symptoms in as little as 2 to 4 weeks.

InflammaDry is a diagnostic test that detects elevated levels of MMP-9, an inflammatory marker consistently found in the tears of patients with DED.

The Tono-Vera Tonometer allows for automated IOP measurements and eliminates the need for a topical anesthetic.

Providing prevention strategies can keep patients comfortable during allergy season.

The microemulsion drug ocular penetration system platform technology was found to effectively formulate and deliver lipophilic molecules via topical eye drops.

Preventive options should be as important as treating symptoms

The diagnostic aid platform, C.DIAG, utilizes artificial intelligence to assist with the diagnosis and treatment of dry eye disease.

The nutritional supplement comprised of a proprietary blend of lutein, zeaxanthin isomers, curcumin, and vitamin D3 improved tear production, tear film break-up time, and tear osmolarity, among others.

UC Berkeley’s Herbert Wertheim School of Optometry and Vision Science integrated the new laser in the beginning of March in its dry eye clinic for treatment of meibomian gland dysfunction.

Evaluating and managing lid margin disease and meibomian gland dysfunction.

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population," which could be due to incomplete eyelid closure, eye discomfort, and mental stress.

Warm compresses are an invaluable step in the treatment of dry eye.

The analysis, which pulled data from the DRy Eye Assessment and Management (DREAM) study, found that users of corticosteroids had multiple worse and consistent DED signs.

Multiple symptomatic improvements, as well as tear film break-up time improvements and a reduction in ocular pain, were noted.

The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play central role in tear film homeostasis.

Education, together with strong recommendations, in-office retail, habit hacks, and follow-up visits, supports patient compliance.

Phase 3 of the randomized, double-masked, placebo-controlled study had a primary end point to evaluate the signs and symptoms of dry eye disease caused by Sjögren syndrome.

By targeting tear evaporation, F6H8 ushers in a new era of dry eye treatment.

Harrow’s Vevye is the first and only cyclosporine-based product approved for the treatment of both signs and symptoms of dry eye disease.

AR-15512 is a topical transient receptor potential melastatin 8 (TRPM8) agonist designed to treat the signs and symptoms of DED via increased tear production.

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

Dry eye disease incidence rates vary markedly depending on the eye care practice.